Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical drug development for dementia with Lewy bodies: past and present
Garam Lee, Jeffrey L. Cummings, Boris Decourt, et al.
Expert Opinion on Investigational Drugs (2019) Vol. 28, Iss. 11, pp. 951-965
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Chemical Knockdown of Phosphorylated p38 Mitogen-Activated Protein Kinase (MAPK) as a Novel Approach for the Treatment of Alzheimer′s Disease
Seung Hwan Son, Na‐Rae Lee, Min Sung Gee, et al.
ACS Central Science (2023) Vol. 9, Iss. 3, pp. 417-426
Open Access | Times Cited: 23
Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers
Lucy L. Gibson, Carla Abdelnour, Joyce R. Chong, et al.
Current Opinion in Neurology (2023)
Open Access | Times Cited: 23
Phytochemicals as Regulators of Genes Involved in Synucleinopathies
Andrei Surguchov, Libby Bernal, Alexei Surguchev
Biomolecules (2021) Vol. 11, Iss. 5, pp. 624-624
Open Access | Times Cited: 49
Drug Discovery and Development Targeting Dementia
Agnieszka Zagórska, Anna Czopek, Monika Fryc, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 2, pp. 151-151
Open Access | Times Cited: 20
Lewy body dementia: Overcoming barriers and identifying solutions
Kanishka Agarwal, Wendi Backler, Ece Bayram, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 3, pp. 2298-2308
Open Access | Times Cited: 6
Adjunct zonisamide to levodopa for DLB parkinsonism
Miho Murata, Toshinari Odawara, Kazuko Hasegawa, et al.
Neurology (2018) Vol. 90, Iss. 8
Open Access | Times Cited: 56
Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials
Jennifer G. Goldman, Leah K. Forsberg, Bradley F. Boeve, et al.
Alzheimer s Research & Therapy (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 40
Dementia with Lewy Bodies Drug Therapies in Clinical Trials: Systematic Review up to 2022
Carla Abdelnour, Maria Camila González, Lucy L. Gibson, et al.
Neurology and Therapy (2023) Vol. 12, Iss. 3, pp. 727-749
Open Access | Times Cited: 15
Screening of small molecules using the inhibition of oligomer formation in α-synuclein aggregation as a selection parameter
Roxine Staats, Thomas C. T. Michaels, Patrick Flagmeier, et al.
Communications Chemistry (2020) Vol. 3, Iss. 1
Open Access | Times Cited: 36
P38α MAPK Signaling—A Robust Therapeutic Target for Rab5-Mediated Neurodegenerative Disease
Ursula A. Germann, John Alam
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 15, pp. 5485-5485
Open Access | Times Cited: 32
On gaps of clinical diagnosis of dementia subtypes: A study of Alzheimer’s disease and Lewy body disease
Hui Wei, Arjun V. Masurkar, Narges Razavian
Frontiers in Aging Neuroscience (2023) Vol. 15
Open Access | Times Cited: 11
Prions and Prion-like assemblies in neurodegeneration and immunity: The emergence of universal mechanisms across health and disease
Ailís O’Carroll, Joanne Coyle, Yann Gambin
Seminars in Cell and Developmental Biology (2019) Vol. 99, pp. 115-130
Closed Access | Times Cited: 28
Projections of costs and quality adjusted life years lost due to dementia from 2020 to 2050: A population‐based microsimulation study
Chiara C. Brück, Frank J. Wolters, M. Arfan Ikram, et al.
Alzheimer s & Dementia (2023) Vol. 19, Iss. 10, pp. 4532-4541
Open Access | Times Cited: 8
Sleep disorders in Lewy body dementia: Mechanisms, clinical relevance, and unanswered questions
Leigh Townsend, Kirstie N. Anderson, Bradley F. Boeve, et al.
Alzheimer s & Dementia (2023) Vol. 19, Iss. 11, pp. 5264-5283
Open Access | Times Cited: 8
A Perspective on Natural and Nature-Inspired Small Molecules Targeting Phosphodiesterase 9 (PDE9): Chances and Challenges against Neurodegeneration
Giovanni Ribaudo, Maurizio Memo, Alessandra Gianoncelli
Pharmaceuticals (2021) Vol. 14, Iss. 1, pp. 58-58
Open Access | Times Cited: 19
Long‐term effects of cholinesterase inhibitors and memantine on cognitive decline, cardiovascular events, and mortality in dementia with Lewy bodies: An up to 10‐year follow‐up study
Hong Xu, Annegret Habich, Daniel Ferreira, et al.
Alzheimer s & Dementia (2024)
Open Access | Times Cited: 2
Epigenetics in Lewy Body Diseases: Impact on Gene Expression, Utility as a Biomarker, and Possibilities for Therapy
Aintzane Urbizu, Katrin Beyer
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 13, pp. 4718-4718
Open Access | Times Cited: 18
The ANeED study – ambroxol in new and early dementia with Lewy bodies (DLB): protocol for a phase IIa multicentre, randomised, double-blinded and placebo-controlled trial
Luiza J. Chwiszczuk, Monica H. Breitve, Bjørn-Eivind Bordewick Kirsebom, et al.
Frontiers in Aging Neuroscience (2023) Vol. 15
Open Access | Times Cited: 6
Emerging drugs for dementia with Lewy Bodies: a review of Phase II & III trials
Magdalena I. Tolea, Reem Ezzeddine, Simone Camacho, et al.
Expert Opinion on Emerging Drugs (2023) Vol. 28, Iss. 3, pp. 167-180
Closed Access | Times Cited: 6
Prospective longitudinal evaluation of cytokines in mild cognitive impairment due to AD and Lewy body disease
Alan Thomas, Calum A. Hamilton, Paul C. Donaghy, et al.
International Journal of Geriatric Psychiatry (2020) Vol. 35, Iss. 10, pp. 1250-1259
Open Access | Times Cited: 17
A53T α-synuclein induces neurogenesis impairment and cognitive dysfunction in line M83 transgenic mice and reduces the proliferation of embryonic neural stem cells
Yu Zhang, Qi Wu, Yu Ren, et al.
Brain Research Bulletin (2022) Vol. 182, pp. 118-129
Closed Access | Times Cited: 9
Identification of a Thyroid Hormone Derivative as a Pleiotropic Agent for the Treatment of Alzheimer’s Disease
Massimiliano Runfola, Michele Perni, Xiaoting Yang, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 12, pp. 1330-1330
Open Access | Times Cited: 11
Phase 2A Learnings Incorporated into RewinD-LB, a Phase 2B Clinical Trial of Neflamapimod in Dementia with Lewy Bodies
Niels D. Prins, Willem de Haan, A Gardner, et al.
The Journal of Prevention of Alzheimer s Disease (2024)
Open Access | Times Cited: 1
Phase 1 Single Ascending and Multiple Ascending Dose Studies of Phosphodiesterase-9 Inhibitor E2027
Ishani Landry, Jagadeesh Aluri, Edgar Schuck, et al.
Alzheimer Disease & Associated Disorders (2022) Vol. 36, Iss. 3, pp. 200-207
Closed Access | Times Cited: 7
The role of blood–brain and blood–retinal barriers in drug delivery
Lorena Bonilla-Vidal, Gerard Esteruelas, Eliana B. Souto, et al.
Elsevier eBooks (2023), pp. 133-154
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top